PURPOSE: Comorbid disease in patients with renal cancer may affect renal cancer prognosis. We estimated the risk of 1 and 5-year mortality in patients with renal cancer in northern Denmark by comorbidity status. MATERIALS AND METHODS: We performed a cohort study tracking mortality in all patients with an incident diagnosis of renal cancer between 1995 and 2006 in a population of 1.6 million residents in northern Denmark. Using hospital discharge data before cancer diagnosis we calculated Charlson comorbidity index scores (0, 1-2 or 3+) in patients with renal cancer as well as absolute survival and relative mortality estimates according to comorbidity level. RESULTS: We identified 2,315 patients with renal cancer, of whom 950 (41%) had comorbidity. The prevalence of comorbidity tended to increase during the study period with the rate in patients with a score of 3+ increasing from 9% to 13%. The 5-year relative mortality rate was lower in patients with a positive Charlson index score with mortality almost twice as high in those with a score of 3+ and 1.2-fold higher in those with a score of 1-2 compared to mortality in those with no comorbidity. Generally similar patterns were observed for 1-year relative mortality. CONCLUSIONS: Comorbidity is common in patients with renal cancer and it is a negative prognostic factor.
PURPOSE: Comorbid disease in patients with renal cancer may affect renal cancer prognosis. We estimated the risk of 1 and 5-year mortality in patients with renal cancer in northern Denmark by comorbidity status. MATERIALS AND METHODS: We performed a cohort study tracking mortality in all patients with an incident diagnosis of renal cancer between 1995 and 2006 in a population of 1.6 million residents in northern Denmark. Using hospital discharge data before cancer diagnosis we calculated Charlson comorbidity index scores (0, 1-2 or 3+) in patients with renal cancer as well as absolute survival and relative mortality estimates according to comorbidity level. RESULTS: We identified 2,315 patients with renal cancer, of whom 950 (41%) had comorbidity. The prevalence of comorbidity tended to increase during the study period with the rate in patients with a score of 3+ increasing from 9% to 13%. The 5-year relative mortality rate was lower in patients with a positive Charlson index score with mortality almost twice as high in those with a score of 3+ and 1.2-fold higher in those with a score of 1-2 compared to mortality in those with no comorbidity. Generally similar patterns were observed for 1-year relative mortality. CONCLUSIONS: Comorbidity is common in patients with renal cancer and it is a negative prognostic factor.
Authors: Matthew R Danzig; Peter Chang; Andrew A Wagner; Mohamad E Allaf; James M McKiernan; Phillip M Pierorazio Journal: Curr Urol Rep Date: 2016-01 Impact factor: 3.092
Authors: Junko Takeshita; Shuwei Wang; Daniel B Shin; Nehal N Mehta; Stephen E Kimmel; David J Margolis; Andrea B Troxel; Joel M Gelfand Journal: JAMA Dermatol Date: 2015-02 Impact factor: 10.282
Authors: Christina G Jespersen; Mette Nørgaard; Truls E Bjerklund Johansen; Mette Søgaard; Michael Borre Journal: BMC Cancer Date: 2011-12-15 Impact factor: 4.430
Authors: Maja S Paulsen; Morten Andersen; Janus L Thomsen; Henrik Schroll; Pia V Larsen; Jesper Lykkegaard; Ib A Jacobsen; Mogens L Larsen; Bo Christensen; Jens Sondergaard Journal: J Am Heart Assoc Date: 2012-12-31 Impact factor: 5.501
Authors: Chandra Sarkar; Hiten Dodhia; James Crompton; Peter Schofield; Patrick White; Christopher Millett; Mark Ashworth Journal: BMC Fam Pract Date: 2015-08-07 Impact factor: 2.497